Prevention & Lipids
Cholesterol treatment and ASCVD risk reduction
Also called cholesterol, dyslipidemia, lipid lowering
Sources: 156 guideline recommendations · 11 landmark trials · 12 new papers · 5 key papers · updated Oct 20, 2026
Updated Nov 7, 2026: 5 experts on Lp(a)HORIZON Extended Analyses
Where experts stand
NEJM Evidence · AHA Scientific Sessions 2026
What 5 experts said about this trial's result
Expert labels are toward Lp(a)HORIZON Extended Analyses's result, from named public quotes (n=5). As of Nov 7, 2026.
The strongest guideline recommendations for lipid management (Class I and IIa). Dosing is left to the guideline.
The use of statins or statin/ezetimibe combination is recommended in patients with non-dialysis-dependent stage 3–5 CKD.
Treatment with statins is recommended for older people with ASCVD in the same way as for younger patients.
In patients who are 75 years of age or younger with clinical ASCVD, high-intensity statin therapy should be initiated or continued with the aim of achieving a 50% or greater reduction in LDL-C levels.
Bempedoic acid is recommended in patients who are unable to take statin therapy to achieve the LDL-C goal.
Unverified · drafted by AI from the sources cited below
Dyslipidemias are abnormalities in the serum levels of lipids, which can include overproduction or deficiency.1 These abnormal serum lipid profiles may involve high total cholesterol, high triglycerides, low high density lipoprotein cholesterol, and elevated low density lipoprotein cholesterol.1
Optimum control of lipids often demands additional measures beyond lifestyle.1 Biological and RNA-directed agents have joined traditional small-molecule approaches for lipid management.1 Recent advances include new treatments targeting triglyceride-rich lipoproteins and lipoprotein(a), and human genetic findings have substantiated novel targets such as apolipoprotein C-III, angiopoietin-like protein 3 and 4, apolipoprotein V, and ATP citrate lyase.
How ESC/EAS 2025 and ESC/EAS 2019 and AHA/ACC 2018 grade each treatment for lipid management. Each chip is that guideline's strongest recommendation; open it for the exact wording and who it applies to.
Statin
Diet
ESC/EAS 2025 · Class I · LOE B
Statin therapy is recommended for people in primary prevention aged ≥40 years with HIV, irrespective of estimated cardiovascular risk and LDL-C levels, to reduce the risk of cardiovascular events; the choice of statin should be based on potential drug interactions.
Primary results of 11 trials behind the evidence on lipid management, as each trial’s own publication reports them.
Left of the line at 1 favours the intervention; square size tracks trial size.Favours the interventionNo significant differenceFavours the comparator
bempedoic acid vs placebo · 13,970 patients · N Engl J Med 2023
In statin-intolerant patients
Primary outcome: a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization
Class of recommendation is how strongly the society advises the action (I is strongest, III is not recommended). Level of evidence is the kind of studies behind it (A is randomized trials, C is expert opinion or limited data).
156 recommendations on lipid management from 3 guidelines, by strength.
Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates
Journal of the American College of Cardiology — Mohebi R
337 citations · 2022 · among the most cited on Lipid management
The dawn of a new era of targeted lipid-lowering therapies
European Heart Journal — Tokgözoğlu L
184 citations · 2021 · among the most cited on Lipid management
Dyslipidemia, inflammation, calcification, and adiposity in aortic stenosis: a genome-wide study
European Heart Journal — Chen H
133 citations · 2023 · among the most cited on Lipid management
Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
The Lancet — Ray K
96 citations · 2025 · among the most cited on Lipid management
Severe Atherogenic Dyslipidemia in Ataxia-Telangiectasia Despite Cachexia: Mechanistic Insights into Mitochondrial Dysfunction
The Yale Journal of Biology and Medicine — Petridis S — Nov 2026
Genome-Wide and Exome-Wide Significant Genetic Variants Influencing Rosuvastatin Therapy: A Scoping Review
Journal of Cardiovascular Pharmacology and Therapeutics — Dermota T — Nov 2026
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
Expert labels are toward each trial's result, from named public quotes.
ESC/EAS 2019 · Class I · LOE A
The use of statins or statin/ezetimibe combination is recommended in patients with non-dialysis-dependent stage 3–5 CKD.
AHA/ACC 2018 · Class I · LOE B-R
In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (≥4.9 mmol/L), maximally tolerated statin therapy is recommended.
High-intensity statin
ESC/EAS 2025 · Class IIa · LOE B
Initiating combination therapy with high-intensity statin plus ezetimibe during index hospitalization for ACS should be considered in patients who were treatment-naïve and are not expected to achieve the LDL-C goal with statin therapy alone.
ESC/EAS 2019 · Class I · LOE A
It is recommended that a high-intensity statin is prescribed up to the highest tolerated dose to reach the goals set for the specific level of risk.
AHA/ACC 2018 · Class I · LOE A
In patients who are 75 years of age or younger with clinical ASCVD, high-intensity statin therapy should be initiated or continued with the aim of achieving a 50% or greater reduction in LDL-C levels.
Ezetimibe
ESC/EAS 2025 · Class IIa · LOE B
Initiating combination therapy with high-intensity statin plus ezetimibe during index hospitalization for ACS should be considered in patients who were treatment-naïve and are not expected to achieve the LDL-C goal with statin therapy alone.
ESC/EAS 2019 · Class I · LOE A
The use of statins or statin/ezetimibe combination is recommended in patients with non-dialysis-dependent stage 3–5 CKD.
AHA/ACC 2018 · Class I · LOE B-NR
In patients with clinical ASCVD who are judged to be very high risk and considered for PCSK9 inhibitor therapy, maximally tolerated LDL-C lowering therapy should include maximally tolerated statin therapy and ezetimibe.
PCSK9 inhibitor
ESC/EAS 2019 · Class I · LOE A
In patients with PAD, lipid-lowering therapy, including a maximum tolerated dose of statin, plus ezetimibe or a combination with a PCSK9 inhibitor if needed, is recommended to reduce the risk of ASCVD events.
AHA/ACC 2018 · Class IIa · LOE A
In patients with clinical ASCVD who are judged to be very high risk and who are on maximally tolerated LDL-C lowering therapy with LDL-C 70 mg/dL or higher (≥1.8 mmol/L) or a non–HDL-C level of 100 mg/dL or higher (≥2.6 mmol/L), it is reasonable to add a PCSK9 inhibitor following a clinician–patient discussion about the net benefit, safety, and cost.
Moderate-intensity statin
AHA/ACC 2018 · Class I · LOE A
In patients with clinical ASCVD in whom high-intensity statin therapy is contraindicated or who experience statin-associated side effects, moderate-intensity statin therapy should be initiated or continued with the aim of achieving a 30% to 49% reduction in LDL-C levels.
Lifestyle therapy
AHA/ACC 2018 · Class I · LOE A
In children and adolescents with lipid disorders related to obesity, it is recommended to intensify lifestyle therapy, including moderate caloric restriction and regular aerobic physical activity.
High-dose statin
ESC/EAS 2019 · Class I · LOE A
In all ACS patients without any contraindication or definite history of intolerance, it is recommended that high-dose statin therapy is initiated or continued as early as possible, regardless of initial LDL-C values.
Bempedoic acid
ESC/EAS 2025 · Class I · LOE B
Bempedoic acid is recommended in patients who are unable to take statin therapy to achieve the LDL-C goal.
Evinacumab
ESC/EAS 2025 · Class IIa · LOE B
Evinacumab should be considered in patients with homozygous familial hypercholesterolaemia aged 5 years or older who are not at LDL-C goal despite receiving maximum doses of lipid-lowering therapy to lower LDL-C levels.
Icosapent ethyl
ESC/EAS 2025 · Class IIa · LOE B
High-dose icosapent ethyl (2 × 2 g/day) should be considered in combination with a statin in high-risk or very high-risk patients with elevated triglyceride levels (fasting triglyceride level 135–499 mg/dL or 1.52–5.63 mmol/L) to reduce the risk of cardiovascular events.
Nonstatin therapy
AHA/ACC 2018 · Class IIa · LOE B-R
In patients at increased ASCVD risk with severe statin-associated muscle symptoms or recurrent statin-associated muscle symptoms despite appropriate statin rechallenge, it is reasonable to use RCT proven nonstatin therapy that is likely to provide net clinical benefit.
Volanesorsen
ESC/EAS 2025 · Class IIa · LOE B
Volanesorsen (300 mg/week) should be considered in patients with severe hypertriglyceridaemia (>750 mg/dL or >8.5 mmol/L) due to familial chylomicronaemia syndrome, to lower triglyceride levels and reduce the risk of pancreatitis.
Fibrate
AHA/ACC 2018 · Class IIa · LOE B-NR
In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), and especially fasting triglycerides ≥1,000 mg/dL (11.3 mmol/L)), it is reasonable to identify and address other causes of hypertriglyceridemia), and if triglycerides are persistently elevated or increasing, to further reduce triglycerides by implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol, consumption of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy.
Omega-3 fatty acids
AHA/ACC 2018 · Class IIa · LOE B-NR
In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), and especially fasting triglycerides ≥1,000 mg/dL (11.3 mmol/L)), it is reasonable to identify and address other causes of hypertriglyceridemia), and if triglycerides are persistently elevated or increasing, to further reduce triglycerides by implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol, consumption of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy.
Bile acid sequestrant
ESC/EAS 2019 · Class IIb · LOE C
If the goal is not achieved, statin combination with a bile acid sequestrant may be considered.
AHA/ACC 2018 · Class IIb · LOE B-R
In patients 20 to 75 years of age with a baseline LDL-C level of 190 mg/dL or higher (≥4.9 mmol/L), who achieve less than a 50% reduction in LDL-C levels and have fasting triglycerides 300 mg/dL or lower (≤3.4 mmol/L), while taking maximally tolerated statin and ezetimibe therapy, the addition of a bile acid sequestrant may be considered.
Bezafibrate
ESC/EAS 2019 · Class IIb · LOE B
In primary prevention patients who are at LDL-C goal with TG levels >2.3 mmol/L (>200 mg/dL), fenofibrate or bezafibrate may be considered in combination with statins.
Fenofibrate
ESC/EAS 2019 · Class IIb · LOE B
In primary prevention patients who are at LDL-C goal with TG levels >2.3 mmol/L (>200 mg/dL), fenofibrate or bezafibrate may be considered in combination with statins.
Coenzyme Q10
AHA/ACC 2018 · Class III · LOE B-R
Coenzyme Q10 is not recommended for routine use in patients treated with statins or for the treatment of SAMS.
Dietary supplements
ESC/EAS 2025 · Class III · LOE B
Dietary supplements or vitamins without documented safety and significant LDL-C-lowering efficacy are not recommended to lower the risk of ASCVD.
HR 0.87 (0.79–0.96)
icosapent ethyl vs placebo · 8,179 patients · N Engl J Med 2019
In patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy
Primary outcome: a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina
HR 0.75 (0.68–0.83)
alirocumab vs placebo · 18,924 patients · N Engl J Med 2018
In patients who had an acute coronary syndrome 1 to 12 months earlier
Primary outcome: a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization
HR 0.85 (0.78–0.93)
evolocumab vs placebo · 27,564 patients · N Engl J Med 2017
In patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy
Primary outcome: the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization
HR 0.85 (0.79–0.92)
simvastatin-ezetimibe vs simvastatin monotherapy · 18,144 patients · N Engl J Med 2015
In patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days
Primary outcome: a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke
HR 0.936 (0.89–0.99)
rosuvastatin vs placebo · 17,802 patients · N Engl J Med 2008
In apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher
Primary outcome: myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes
HR 0.56 (0.46–0.69)
atorvastatin vs placebo · 4,731 patients · N Engl J Med 2006
In patients who had had a stroke or TIA within one to six months before study entry
Primary outcome: a first nonfatal or fatal stroke
HR 0.84 (0.71–0.99)
80 mg of atorvastatin vs 10 mg of atorvastatin · 10,001 patients · N Engl J Med 2005
In patients with clinically evident CHD and LDL cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter)
Primary outcome: the occurrence of a first major cardiovascular event, defined as death from CHD, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke
HR 0.78 (0.69–0.89)
atorvastatin vs placebo · 10,305 patients · Lancet 2003
In hypertensive patients (aged 40-79 years with at least three other cardiovascular risk factors)
Primary outcome: non-fatal myocardial infarction and fatal CHD
HR 0.64 (0.50–0.83)
ORION-10day 510 placebo-corrected % change
inclisiran vs placebo · 1,561 patients · N Engl J Med 2020
Primary outcome: the placebo-corrected percentage change in LDL cholesterol level from baseline to day 510
“by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial”
ORION-10time-adjusted % change after day 90 up to day 540
inclisiran vs placebo · 1,561 patients · N Engl J Med 2020
Primary outcome: the time-adjusted percentage change in LDL cholesterol level from baseline after day 90 and up to day 540
“time-adjusted reductions of 53.8% (95% CI, 51.3 to 56.2)”
ORION-11day 510 placebo-corrected % change
inclisiran vs placebo · 1,617 patients · N Engl J Med 2020
Primary outcome: the placebo-corrected percentage change in LDL cholesterol level from baseline to day 510
“by 49.9% (95% CI, 46.6 to 53.1) in the ORION-11 trial”
ORION-11time-adjusted % change after day 90 up to day 540
inclisiran vs placebo · 1,617 patients · N Engl J Med 2020
Primary outcome: the time-adjusted percentage change in LDL cholesterol level from baseline after day 90 and up to day 540
“and 49.2% (95% CI, 46.8 to 51.6)”
Results are quoted from each trial’s primary publication abstract (PubMed); the trial name links to the paper. Ratios below 1 favour the intervention.
Class IClass IIaClass IIbClass III
The strongest 20 recommendations
In primary prevention, pharmacological LDL-C-lowering therapy is recommended in persons: • at very high risk and LDL-C ≥1.8 mmol/L (70 mg/dL), or • at high risk and LDL-C ≥2.6 mmol/L (100 mg/dL) despite optimization of non-pharmacological measures, to lower CVD risk.
SCORE2 is recommended in apparently healthy people <70 years of age without established ASCVD, DM, CKD, genetic/rare lipid or BP disorders for estimation of 10-year fatal and non-fatal CVD risk.
SCORE2-OP is recommended in apparently healthy people ≥70 years of age without established ASCVD, DM, CKD, genetic/rare lipid or BP disorders for estimation of 10-year fatal and non-fatal CVD risk.
Non-statin therapies with proven cardiovascular benefit, taken alone or in combination, are recommended for patients who are unable to take statin therapy to lower LDL-C levels and reduce the risk of CV events. The choice should be based on the magnitude of additional LDL-C lowering needed.
Bempedoic acid is recommended in patients who are unable to take statin therapy to achieve the LDL-C goal.
Intensification of lipid-lowering therapy during the index ACS hospitalization is recommended for patients who were on any lipid-lowering therapy before admission in order to further lower LDL-C levels.
Statin therapy is recommended for people in primary prevention aged ≥40 years with HIV, irrespective of estimated cardiovascular risk and LDL-C levels, to reduce the risk of cardiovascular events; the choice of statin should be based on potential drug interactions.
In all ACS patients without any contraindication or definite history of intolerance, it is recommended that high-dose statin therapy is initiated or continued as early as possible, regardless of initial LDL-C values.
Patients with a history of ischaemic stroke or TIA are at very high-risk of ASCVD, particularly recurrent ischaemic stroke, so it is recommended that they receive intensive LDL-C-lowering therapy.
It is recommended that patients with Kidney Disease Outcomes Quality Initiative stage 3–5 CKD are considered to be at high or very-high risk of ASCVD.
In patients who are 75 years of age or younger with clinical ASCVD, high-intensity statin therapy should be initiated or continued with the aim of achieving a 50% or greater reduction in LDL-C levels.
In patients with clinical ASCVD in whom high-intensity statin therapy is contraindicated or who experience statin-associated side effects, moderate-intensity statin therapy should be initiated or continued with the aim of achieving a 30% to 49% reduction in LDL-C levels.
Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease
Journal of the American College of Cardiology — Hess C
54 citations · 2021 · among the most cited on Lipid management
Associations of cumulative exposure and dynamic trajectories of the combined atherogenic-frailty index with incident cardiometabolic multimorbidity: a prospective cohort study
Journal of Global Health — 巫海娣 — Oct 2026
The use of statins or statin/ezetimibe combination is recommended in patients with non-dialysis-dependent stage 3–5 CKD.
In patients with PAD, lipid-lowering therapy, including a maximum tolerated dose of statin, plus ezetimibe or a combination with a PCSK9 inhibitor if needed, is recommended to reduce the risk of ASCVD events.
In secondary prevention for patients at very-high risk, an LDL-C reduction of ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended.
In patients at high risk, an LDL-C reduction of ≥50% from baseline and an LDL-C goal of <1.8 mmol/L (<70 mg/dL) are recommended.
In adults 40 to 75 years of age with diabetes mellitus, regardless of estimated 10-year ASCVD risk, moderate-intensity statin therapy is indicated.
In adults at intermediate-risk, statin therapy reduces risk of ASCVD, and in the context of a risk discussion, if a decision is made for statin therapy, a moderate-intensity statin should be recommended.
In intermediate-risk patients, LDL-C levels should be reduced by 30% or more, and for optimal ASCVD risk reduction, especially in high-risk patients, levels should be reduced by 50% or more.
Adherence to changes in lifestyle and effects of LDL-C–lowering medication should be assessed by measurement of fasting lipids and appropriate safety indicators 4 to 12 weeks after statin initiation or dose adjustment and every 3 to 12 months thereafter based on need to assess adherence or safety.